We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > LT3001

News List

Lumosa Therapeutics Announces Positive Results from Phase 2 Stroke Clinical Trial americanpharmaceuticalreview
August 04, 2021
Lumosa Therapeutics announced that its Phase 2a clinical trial of LT3001 successfully met its primary safety endpoint.
Lumosa to Initiate Phase 2 Human Clinical Trial for LT3001 to treat Acute Ischemic Stroke biospectrumasia
June 16, 2019
Enrolment process to accelerate in the US and Taiwan, China for Safety, tolerability and pharmacokinetic exploration of the novel drug
Enrollment of first human subject for Lumosa Therapeutics’ LT3001 trial pharmaasia
August 15, 2017
The first human subject was dosed with LT3001 in California, USA on 28 July 2017, with the trial to evaluate the safety and pharmacokinetics of LT3001 expected to be completed in early 2018.